<DOC>
	<DOCNO>NCT00002178</DOCNO>
	<brief_summary>To determine proportion patient whose plasma HIV-1 RNA level fall level detection ( &lt; 400 copies/ml ) week 16 24 study therapy . To determine absolute change plasma HIV-1 RNA absolute CD4 cell count 24 week study treatment . To collect safety data treatment regimen . To determine percentage patient without SQV soft gel capsule resistance-associated mutation week 24 .</brief_summary>
	<brief_title>A Phase IIIB Open-Label , Comparative Study Evaluate Saquinavir Soft Gel Capsule ( SGC ) Treatment Combination With Other Antiretrovirals HIV-1 Infected Antiretroviral-Naive Patients</brief_title>
	<detailed_description>Patients randomize receive 1 3 study regimen : Group A - Saquinavir ( SQV ) soft gel capsule ( sgc ) plus 2 reverse transcriptase inhibitor ( RTIs ) , Group B - SQV sgc plus delavirdine plus RTI , Group C - SQV sgc plus nelfinavir plus RTI ( SQV sgc plus ritonavir plus 2 RTIs ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV RNA &gt; = 5000 copies/ml Amplicor assay . Signed , inform consent parent legal guardian patient le 18 year old . Previous treatment antiretrovirals .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Dosage Forms</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>